Psychiatr. pro Praxi, 2007; 3: 141-144

Dosage of lamotrigine

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

Lamotrigine, a new antiepileptic drug, is also a well-established drug in psychiatry. Its main indication is the bipolar disorder, but lamotrigine has been tried in other indications as well, for example as an augmentation in both pharmacoresistant depressive and schizophrenic disorders. Lamotrigine is a promising drug due to its mechanism of action and profile of side effects. Nowadays, lamotrigine is supplied under various trade names by many generic pharmaceutical companies. However, so far the optimal effective dose is not entirely clear. Most of the open and controlled studies have shown that the daily dose after the titration should not be lower than 200 mg. The survey of studies confirming this fact is discussed.

Keywords: lamotrigine, effective dose, bipolar disorder, unipolar depression, schizophrenia

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Dosage of lamotrigine. Psychiatr. praxi. 2007;8(3):141-144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy 2005; 2: 399-406. Go to original source...
    2. Baloescu A, Grigrescu G, Gheorghe MD. Lamotrigine in the treatment of resistant depression. Eur Psychiatry 2006; 21: S154. Go to original source...
    3. Barbora L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episode. J Clin Psychiatry 2003; 64: 403-407. Go to original source... Go to PubMed...
    4. Bowden CL, Calabrese JR, McElroy SL et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953-958. Go to original source... Go to PubMed...
    5. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400. Go to original source... Go to PubMed...
    6. Bowden CL, Asnis GM, Gingsberg LD et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-184. Go to original source... Go to PubMed...
    7. Calabrese JR, Bowden CL, McElroy SL et al. Spectrum of activity of lamotrigine in treatmentrefractory bipolar disorder. Am J Psychiatry 1999; 156: 1019-1023. Go to original source... Go to PubMed...
    8. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88. Go to original source... Go to PubMed...
    9. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-850. Go to original source... Go to PubMed...
    10. Calabrese JR, Suppes T, Bowden CL et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024. Go to original source... Go to PubMed...
    11. Češková E, Pálenský V, Skotáková S. Současné možnosti farmakoterapie deprese. Čes. a slov. Psychiatrie 2004 100: 148-152.
    12. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia (letter). Arch Gen Psychiatry 1999; 56: 950. Go to original source... Go to PubMed...
    13. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001; 15: 297-301. Go to original source... Go to PubMed...
    14. Edelbroek PM, Segers JP, Gilissen KGPM, et al. Population pharmacokinetic of lamotrigine to evaluace interaction with concomitant antiepileptic drugs. Epilpepsia 1996; 37 (suppl. 4): 64.
    15. Fatemi SH, Rapport DJ, Calabrese JR et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58: 522-527. Go to original source... Go to PubMed...
    16. Fornaro P, Cultera S, Lunardi G et al. Clinical effects and plasma levels of lamotrigine in depressed outpatients: preliminary results from an open trial (abstract). Biol Psychiatry 1997; 42 (suppl 1): 41S. Go to original source...
    17. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory moood disorders. J Clin Psychopharmacol 2000; 20: 607-614. Go to original source... Go to PubMed...
    18. Hamer RM, Simpson PM. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder (letter). Biol Psychiatry 1999; 46: 1711-1712. Go to original source... Go to PubMed...
    19. Heck AH, deGroot IW, van Harten PN. Addition of lamotrigine to clozapine in in-patients with chronic psychosis (letter). J Clin Psychiatry 2005; 66: 1333. Go to original source... Go to PubMed...
    20. Khan A, Ginsberg LD, Asnis GM et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry, 2004; 65: 1483-1490. Go to original source... Go to PubMed...
    21. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G. Long-term lamotrigine adjunctive antipsychotic monotherapy in schizophrenia: further evidence. Can J Psychiatry 2004; 49: 280. Go to original source... Go to PubMed...
    22. Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56: 441-446. Go to original source... Go to PubMed...
    23. Kusumukar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145-148. Go to original source... Go to PubMed...
    24. Londborg P, Cutler N, Cunninghan L et al. Lamotrigine in the treatment of unipolar depression. Presented at the 152nd annual meeting of the APA May 15-20, 1999; Washington DC.
    25. Meldrum BD. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 (suppl 6): S4-S11. Go to original source... Go to PubMed...
    26. Normann C, Hummel B, Schärer LO et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002; 63: 337-344. Go to original source... Go to PubMed...
    27. Saba G, Dumortier G, Kalalou K et al.: Lamotrigine-clozapine combination in refractory schizophrenia: three cases (letter). J Neuropsychiatry Clin Neurosci 2002; 14: 86. Go to original source... Go to PubMed...
    28. Zabere A., Dam M, A-Rogvi-Hansen B et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109: 9-13. Go to original source... Go to PubMed...
    29. Schindler F, Anghelescu I. The LILA-Study: An observational study comparing the efficacy of lithium vs lamotrigine as an augmentation strategy for treatment-resistant depression (TRD). Biol Psychiatry 2004; 55: S40.
    30. Smith D, Chadwick D, Baker G. et al. Seizure severity and the duality of life. Epilepsia 1993; 34 (suppl 5): S31-S35. Go to original source... Go to PubMed...
    31. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185-189. Go to original source... Go to PubMed...
    32. Suppes T, Brown SE, McElroy S et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affective Disorders 1999; 53: 95-98. Go to original source... Go to PubMed...
    33. Tiihonen J, Hallikainen T, Ryynäneb O-P et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-1248. Go to original source... Go to PubMed...
    34. Walden J, Schaerer L, Schloesser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disorders 2000; 2: 336-339. Go to original source... Go to PubMed...
    35. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119-130. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.